CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Dublin, Feb. 05, 2018 -- The "Global Osteoporosis Partnering 2010 to 2017" report has been added to ResearchAndMarkets.com's offering.
The Global Osteoporosis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.
The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Summary:
- In-depth understanding of deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to multiple deals entered into by the world's biopharma companies since 2010
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Features
- Trends in partnering deals
- Top deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
Key Topics Covered:
Executive Summary
Chapter 1 - Therapy partnering trends in numbers
- Partnering in numbers - by year
- Partnering in numbers - most active
- Partnering in numbers - by industry sector
- Partnering in numbers - by deal type
- Partnering in numbers - by technology type
- Partnering in numbers - by stage of development
Chapter 2 - Most active dealmakers
Chapter 3 - Partnering deals directory
- Partnering deals directory - by company A-Z
- Partnering deals directory - by deal value
- Partnering deals directory - by industry sector
- Partnering deals directory - by deal type
- Partnering deals directory - by stage of development
- Partnering deals directory - by technology area
Chapter 4 - Partnering deals with a contract document
Chapter 5 - M&A in numbers
- M&A in numbers - by year
Chapter 6 - M&A deals directory
- M&A deals directory - by company A-Z
- M&A deals directory - by deal value
Chapter 7 - Financing in numbers
- Financing in numbers - by year
- Financing in numbers - by financing type
Chapter 8 - Financing deals directory
- Financing deals directory - by company A-Z
- Financing deals directory - by deal value
- Financing deals directory - by financing type
For more information about this report visit https://www.researchandmarkets.com/research/kpxjmc/global?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Musculoskeletal Disorders Drugs
